Navigation Links
MPs in Biological Technology

Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision

Announces significant contract with Major Biopharmaceutical Company BELGIUM, Wis., March 6 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), is pleased to announce that its subsidiary, Modular Process Constructors LLC, is changing its name to MPS BioPharm to better reflect i...

BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome

NOVATO, Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced its program for its third enzyme replacement therapy (ERT) for the treatment of mucopolysaccharidosis IVA (MPS IVA), or Morquio A Syndrome. BioMarin plans to initiate a Phase 1/2...

Kuvan Receives Priority Review Status From Health Canada

...ment for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase 1/2 clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Jefferies Healthcare Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Goldman Sachs Healthcare Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Deutsche Bank Health Care Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin to Present at the Baird Growth Stock Conference

...ent for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of mps IVA. For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press relea...

BioMarin Announces First Quarter 2009 Financial Results

...g programs including PEG-PAL for PKU and GALNS for mps IVA. We are strategically developing earlier stag...ial are expected in mid-2010. GALNS for mps IVA: BioMarin initiated the Phase I/II trial in m... 1H10: Results from Phase I/II trial for GALNS for mps IVA Mid-2010: Results from PEG-PAL Phase I...

Mach One BioPharm Process Operating Group Receives Contract From American Beef Processors

...ilize MPS' Equity by Design (TM) product. mps will evaluate all equipment designs for fit and pu...lated to design, constructability and cleanliness. mps will also provide a final report, identifying budg...id, "Equity by Design(TM) is a program whereby mps provides certain Technical Advisory Services in wh...

BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA

...me replacement therapies, one for the treatment of mps I and one for the treatment of mps VI. Naglazyme(R) (galsulfase) for mps VI is wholly developed and commercialized by BioMa...

BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results

...the advancement of several programs including PEG-PAL for PKU and GALNS for mps IVA. We also plan to continue making investments in growth opportunities a...se 2 PAH trial -- 1Q09/2Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 2Q09: Results from proteinuria in chronic kidney disease trial ...

Naglazyme Approved by Brazil's National Health Surveillance Agency

...zil which has the largest known number of affected mps VI patients in the world," said Stephen Aselage, S...) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...t exclusivity in the European Union. About mps VI ...

Mach One Corporation Enters Letter of Intent

...saction with Modular Process Constructors LLC (dba mps BioPharm) (the "Seller" or "BioPharm") to acquire ... About Modular Process Constructors LLC (dba mps BioPharm) mps BioPharm currently designs and builds skid based s...

Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics

... (galsulfase) and enzyme replacement therapies for mps IVA (Morquio Syndrome) and Pompe disease will be p...for symptomatic spinal cord compression (SCC) in a mps VI child: safety, efficacy, and pitfalls" 763/W ...ears of Galsulfase ERT in five adult patients with mps VI" 2353/W - "MPS Brazil-Network: 4 years improv...

BioMarin Announces Third Quarter 2008 Financial Results

...xpansion of Naglazyme, and the timely development of the PEG-PAL, GALNS for mps IVA and other promising pipeline programs." Net Product Revenue Net pro...ic kidney disease trial -- 1Q09: Initiation of Phase 1 trial for GALNS for mps IVA -- 1Q09/2Q09: Results from PEG-PAL Phase 1 trial -- 1Q09/2Q09: Initia...

Naglazyme Approved by Japanese Ministry of Health

...Ges in bringing the first drug treatment option to mps VI patients in Japan," said Stephen Aselage, Senio...C) in January 2006. As the first drug approved for mps VI, the FDA and EC have both designated Naglazyme ...ation in June 2007 from the MHLW in Japan. About mps VI ...

BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture

...rojects which could lead to important advances for mps I patients." About mps I mps I is a rare, progressive, heterogeneous, debilitat...

Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics

...e (galsulfase) Enzyme Replacement Therapy (ERT) in mps VI (Maroteaux-Lamy Syndrome) patients Presented b...sserstein) -- 1495 -- Clinical Characteristics of mps I patients in the mps I Registry (Bodamer) -- 2241 -- Urinary GAG ...

Genzyme Receives Approval to Market Elaprase(R) in Japan

... Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease; Fabrazyme(R) (agalsidase beta) for Fabry disease; Aldurazyme(R) (laronidase) for mps I; and Myozyme(R) (alglucosidase alfa) for Pompe disease. "Our deep experience in Japan in the area of lysosomal storage disorders will enable us to ...

Genzyme Begins Major Expansion of Boston Manufacturing Facility

... alfa) for Pompe disease. Genzyme also performs the filling and packaging for two products manufactured at other sites: Aldurazyme(R) (laronidase) for mps I disease and Thyrogen(R) (thyrotropin alfa for injection), used in the screening of patients who have had thyroid cancer. Genzyme last expanded the s...

Educate, innovate and execute: Wisconsins model for success

...m rather than how much is spent administratively. mps simply spends too much money on employee costs (i....nefits, pension) than is manageable. In fact, the mps Board boosted the tax levy for 2003-'04 by more th...$11 million, or a 5.8 percent increase. This year, mps is projecting a 15% increase as a stopgap to keep ...
Other Tags
(Date:2/10/2015)... -- Alere Inc. (NYSE: ALR), a global leader in ... quarter ended December 31, 2014. Namal ... said, "We made substantial progress in the fourth ... in rapid diagnostics and delivering against our financial ... early January enabled us to substantially reduce our ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
(Date:3/5/2015)... The Maricopa Community Colleges add $7.3 ... economy each year, according to a research report released ... Maricopa County Community College District, summarizes economic impact and ... year 2013-2014. , The analysis was conducted by ... that specializes in providing economic impact studies and labor ...
(Date:3/5/2015)... March 05, 2015 At the ... Beyond,” leaders in addiction treatment met today in Jackson, ... best clinical practices. Among the numerous respected speakers will ... will address the role that pain medications have had ... evidence-based treatment options. , "It is hard to believe ...
(Date:3/5/2015)... Taking center stage at the Fort ... 9-11th is IDRevolution hosted by IDLife LLC, a ... IDLife offers a variety of nutritional products including ... to vitamin supplementation is based upon the latest ... compliant online assessment and ends with a truly ...
(Date:3/5/2015)... NC (PRWEB) March 05, 2015 ... Physician Assistants’ (AAPA) review of Clearstream, LLC ... determined that Clearstream’s MediDefense line of products—led by ... the AAPA’s Affinity Partner Program. , The AAPA—which ... assistants across all medical and surgical specialties in ...
(Date:3/5/2015)... Jordan Valley Medical Center is now utilizing ... for sudden cardiac arrest. When a patient wears this ... any life-threatening abnormalities. If an abnormal heart rhythm is ... a treatment shock to restore normal rhythm to the ... Medical Center and the Heart and Lung Institute of ...
Breaking Medicine News(10 mins):Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 2Health News:Maricopa Community Colleges Add $7.3 Billion to Local Economy Annually 3Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:IDLife Partners John C. Maxwell and Troy Aikman speaking at IDRevolution in Fort Worth, TX April 9th-11th, 2015 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 2Health News:New Technology Behind LifeVest® Wearable Defibrillator Saves the Life of Utah Man in Cardiac Arrest 3
Other Contents